|
EP0883344B2
(en)
|
1995-12-15 |
2010-06-09 |
VIRxSYS Corporation |
Therapeutic molecules generated by trans-splicing
|
|
US6280978B1
(en)
|
1995-12-15 |
2001-08-28 |
Intronn Holdings, Llc |
Methods and compositions for use in spliceosome mediated RNA trans-splicing
|
|
EP0938381B1
(en)
|
1996-10-04 |
2012-12-26 |
Veri-Q Inc. |
Sample collection devices and methods using markers and the use of such markers as controls in sample validation, laboratory evaluation and/or accreditation
|
|
US6929907B2
(en)
|
1999-12-31 |
2005-08-16 |
North Carolina State University |
Methods and compositions for determining the purity of chemically synthesized nucleic acids
|
|
CA2452690C
(en)
|
2001-06-29 |
2016-08-16 |
Veri-Q, Inc. |
Methods and compositions for determining the purity of and purifying chemically synthesized nucleic acids
|
|
AU2003215249B2
(en)
|
2002-02-12 |
2008-07-03 |
Virxsys Corporation |
Methods and compositions for use in spliceosome mediated RNA trans-splicing
|
|
US7399753B2
(en)
|
2002-02-25 |
2008-07-15 |
Virxsys Corporation |
Trans-splicing mediated photodynamic therapy
|
|
CA2477295A1
(en)
|
2002-02-25 |
2003-09-04 |
Intronn, Inc. |
Trans-splicing mediated imaging of gene expression
|
|
AU2003247505A1
(en)
|
2002-06-05 |
2003-12-22 |
University Of Iowa Research Foundation |
Spliceosome mediated rna trans-splicing in stem cells
|
|
WO2003104412A2
(en)
|
2002-06-05 |
2003-12-18 |
Intronn, Inc. |
Spliceosome mediated rna trans-splicing and correction of factor viii genetic defects using spliceosome mediated rna trans spling
|
|
US20040018622A1
(en)
|
2002-07-17 |
2004-01-29 |
Mitchell Lloyd G. |
Spliceosome mediated RNA trans-splicing for correction of skin disorders
|
|
AU2003285009B2
(en)
|
2002-10-23 |
2010-10-07 |
Virxsys Corporation |
Screening methods for identification of efficient pre-trans-splicing molecules
|
|
WO2005070948A1
(en)
|
2004-01-23 |
2005-08-04 |
Intronn, Inc. |
Correction of alpha-1-antitrypsin genetic defects using spliceosome mediated rna trans splicing
|
|
US7968334B2
(en)
|
2004-01-23 |
2011-06-28 |
Virxsys Corporation |
Expression of apoAI and variants thereof using spliceosome mediated RNA trans-splicing
|
|
WO2005070023A2
(en)
|
2004-01-23 |
2005-08-04 |
Intronn, Inc. |
Expression of apoa-1 and variants thereof using spliceosome mediated rna trans-splicing
|
|
WO2006026611A2
(en)
|
2004-08-31 |
2006-03-09 |
Mitchell Lloyd G |
Reverse transcriptase mediated rna gene expression
|
|
US7943374B2
(en)
|
2005-08-21 |
2011-05-17 |
Markus Hildinger |
Super-size adeno-associated viral vector harboring a recombinant genome larger than 5.7 kb
|
|
US20090214478A1
(en)
|
2008-02-21 |
2009-08-27 |
Alberto Auricchio |
Method of treating ocular diseases by gene therapy
|
|
US8236557B2
(en)
|
2008-05-28 |
2012-08-07 |
University Of Missouri-Columbia |
Hybrid-AAV vectors to deliver large gene expression cassette
|
|
EP2151248A1
(en)
|
2008-07-30 |
2010-02-10 |
Johann Bauer |
Improved pre-mRNA trans-splicing molecule (RTM) molecules and their uses
|
|
EP2486136B1
(en)
|
2009-10-08 |
2016-03-30 |
Association Institut de Myologie |
Nucleic acid molecules and methods for exchanging exon(s) by transsplicing
|
|
US8648053B2
(en)
|
2010-10-20 |
2014-02-11 |
Rosalind Franklin University Of Medicine And Science |
Antisense oligonucleotides that target a cryptic splice site in Ush1c as a therapeutic for Usher syndrome
|
|
US9249425B2
(en)
|
2011-05-16 |
2016-02-02 |
The Trustees Of The University Of Pennslyvania |
Proviral plasmids and production of recombinant adeno-associated virus
|
|
ES2646716T3
(es)
|
2011-09-05 |
2017-12-15 |
Stichting Katholieke Universiteit |
Oligonucleótidos antisentido para el tratamiento de amaurosis congénita de Leber
|
|
CN105120901A
(zh)
|
2012-07-11 |
2015-12-02 |
宾夕法尼亚大学托管会 |
Rpgr x染色体连锁视网膜退化的aav介导的基因治疗
|
|
CN104955951A
(zh)
|
2012-10-16 |
2015-09-30 |
麻省理工学院 |
稳定的非多腺苷酸化rna的产生
|
|
DK2986635T3
(en)
|
2013-04-18 |
2019-01-28 |
Fond Telethon |
EFFECTIVE DELIVERY OF BIG GENES THROUGH DUAL-AAV VECTORS
|
|
US9938521B2
(en)
|
2014-03-10 |
2018-04-10 |
Editas Medicine, Inc. |
CRISPR/CAS-related methods and compositions for treating leber's congenital amaurosis 10 (LCA10)
|
|
LT3167076T
(lt)
*
|
2014-07-09 |
2022-02-10 |
Lexogen Gmbh |
Metodai ir produktai, skirti rnr transkripto variantų kiekybiniam įvertinimui
|
|
CN107109411B
(zh)
|
2014-10-03 |
2022-07-01 |
冷泉港实验室 |
核基因输出的定向增加
|
|
AU2016355343C1
(en)
*
|
2015-11-19 |
2024-10-03 |
Lloyd G. Mitchell |
Compositions and methods for correction of heritable ocular disease
|
|
JP7036723B2
(ja)
|
2015-12-14 |
2022-03-15 |
コールド スプリング ハーバー ラボラトリー |
眼疾患の処置のための組成物および方法
|
|
US11096956B2
(en)
|
2015-12-14 |
2021-08-24 |
Stoke Therapeutics, Inc. |
Antisense oligomers and uses thereof
|
|
WO2017171654A1
(en)
|
2016-04-01 |
2017-10-05 |
National University Of Singapore |
Trans-splicing rna (tsrna)
|
|
US11795455B2
(en)
|
2017-07-31 |
2023-10-24 |
Massachusetts Institute Of Technology |
RNA cleavage-induced transcript stabilizer and uses thereof
|
|
KR20260009385A
(ko)
|
2017-08-25 |
2026-01-19 |
스톡 테라퓨틱스, 인크. |
병태 및 질환 치료용 안티센스 올리고머
|
|
MX2020009579A
(es)
*
|
2018-03-15 |
2020-11-09 |
Intergalactic Therapeutics Inc |
Vectores de adn sintetico y metodos de uso.
|
|
KR20250150157A
(ko)
*
|
2018-04-17 |
2025-10-17 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
트랜스-스플라이싱 분자
|
|
BR112021020539A2
(pt)
|
2019-04-17 |
2022-01-04 |
Univ Pennsylvania |
Terminador de hélice tripla para trans-splicing de rna eficiente
|
|
WO2020214990A1
(en)
*
|
2019-04-17 |
2020-10-22 |
Ascidian Therapeutics, Inc. |
Abca4 cell line and methods of use
|
|
CN113795155A
(zh)
*
|
2019-05-01 |
2021-12-14 |
宝洁公司 |
产生短链脂肪酸的益生菌菌株和包含该益生菌菌株的组合物
|
|
EP4013873A1
(en)
|
2019-08-16 |
2022-06-22 |
Massachusetts Institute Of Technology |
Targeted trans-splicing using crispr/cas13
|
|
WO2021076656A1
(en)
|
2019-10-15 |
2021-04-22 |
University Of Massachusetts |
Rna editor-enhanced rna trans-splicing
|
|
EP3992292A4
(en)
|
2020-02-28 |
2023-06-21 |
Rznomics Inc. |
APOE4 RNA-SPECIFIC TRANSSPLICING RIBOZYME AND ITS USE
|
|
EP4217010A4
(en)
|
2020-09-28 |
2025-01-08 |
Tacit Therapeutics, Inc. |
TRANS-SPLICING SYSTEM FOR TISSUE-SPECIFIC REPLACEMENT OF RNA SEQUENCES
|
|
EP4323391A4
(en)
|
2021-04-15 |
2025-04-16 |
Tacit Therapeutics, Inc. |
HIGH-EFFICIENCY TRANS-SPLICING FOR TARGETED RNA SEQUENCE REPLACEMENT IN HUMAN CELLS
|
|
JP2024533163A
(ja)
|
2021-09-03 |
2024-09-12 |
タシト・セラピューティクス・インコーポレーテッド |
スプライソソーム構成要素のリクルートを介したrna編集
|
|
WO2023205694A2
(en)
|
2022-04-20 |
2023-10-26 |
Tacit Therapeutics, Inc. |
Stabilization of therapeutic trans-splicing rna molecules in human cells
|
|
EP4519436A4
(en)
|
2022-05-03 |
2026-08-19 |
Tacit Therapeutics Inc |
LOCALIZATION OF NUCLEIC ACID MOLECULES TRANS-SPLICING TO AND WITHIN THE CELL NUCLEUS
|
|
KR20250011939A
(ko)
|
2022-05-13 |
2025-01-22 |
아시디엔 테라퓨틱스, 인크. |
Abca4 트랜스-스플라이싱 분자
|